Biohaven Ltd. Files 8-K Report

TL;DR

Biohaven Ltd. filed an 8-K on Oct 2, 2024, covering other events and financial exhibits.

AI Summary

On October 2, 2024, Biohaven Ltd. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." It also notes a former company name, Biohaven Research Ltd., with a name change date of June 29, 2022.

Why It Matters

This 8-K filing serves as an official notification to the SEC and the public about significant corporate events or financial updates for Biohaven Ltd.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of corporate events and financial information, not indicating any immediate financial distress or significant operational change.

Key Players & Entities

• Biohaven Ltd. (company) — Registrant
• Biohaven Research Ltd. (company) — Former company name
• October 2, 2024 (date) — Date of report
• June 29, 2022 (date) — Date of name change

FAQ

Key Financial Figures

• $47.50 — mon shares, at a price to the public of $47.50 per common share. On October 2, 2024, t
• $287.5 million — able by the Company, were approximately $287.5 million. As of September 30, 2024, without inc

Filing Documents

• bhvn-20241002.htm (8-K) — 26KB
• exhibit11-closing8xk10224.htm (EX-1.1) — 244KB
• exhibit51-closing8xk10224.htm (EX-5.1) — 25KB
• image_0.jpg (GRAPHIC) — 11KB
• image_1.jpg (GRAPHIC) — 18KB
• 0001628280-24-041894.txt ( ) — 511KB
• bhvn-20241002.xsd (EX-101.SCH) — 2KB
• bhvn-20241002_lab.xml (EX-101.LAB) — 21KB
• bhvn-20241002_pre.xml (EX-101.PRE) — 12KB
• bhvn-20241002_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On September 30, 2024, Biohaven Ltd. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, as representatives of the several underwriters named therein, in connection with the registered public offering (the "Offering") of up to 6,052,631 of the Company's common shares, including the underwriters' option to purchase 789,473 additional common shares, at a price to the public of $47.50 per common share. On October 2, 2024, the Company issued and sold 6,052,631 of its common shares pursuant to the Underwriting Agreement, which included the exercise in full of the underwriters' option to purchase additional common shares. The aggregate gross proceeds to the Company from the Offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, were approximately $287.5 million. As of September 30, 2024, without including the 6,052,631 common shares issued in the offering, the Company had 94,899,193 common shares, without par value per share, outstanding. The Underwriting Agreement contains customary representations, warranties and agreements of the Company, conditions to closing, indemnification rights and obligations of the parties and termination provisions. A copy of the underwriting agreement is attached as Exhibit 1.1 to this Current Report on Form 8-K and incorporated by reference herein. The Offering was made pursuant to an effective shelf registration statement (the "Registration Statement") filed with the Securities and Exchange Commission on October 2, 2023 (File No. 333-274822), a base prospectus, dated October 2, 2023, included as part of the Registration Statement, and a prospectus supplement, dated September 30, 2024, filed with the Securities and Exchange Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended. A copy of the opinion of Maples & Calder relating to the issu

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 1.1 Underwriting Agreement, dated as of September 30, 2024, by and between the Company and J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC, as representatives of the several underwriters. 5.1 Opinion of Maples & Calder. 23.1 Consent of Maples & Calder (included in Exhibit 5.1). 104 The cover page of this Current Report on Form 8-K formatted as Inline XBRL.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Biohaven Ltd. By: /s/ Vlad Coric, M.D. Date: October 2, 2024 Vlad Coric, M.D. Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR